ELTX
Elicio Therapeutics, Inc.
$13.55
+2.19%
$258.6M
No data for this timeframe.
Vol
Market Cap$258.6M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders5 funds
Inst. Value$4.3M
Inst. Activity1 buys / 2 sells
SEC Reports3
Press Releases1
Recent Activity
May 12, 2026
short_interest
FTD: ELTX — 61,210 shares ($0.7M) failed to deliver
Settlement: 20260512, Price: $11.61, FTD Value: $710,648.1, ELICIO THERAPEUTICS INC COM
May 11, 2026
SEC
Elicio Therapeutics reported Q1 2026 results with a net loss of $11.8M ($0.65 per share), wider than the $11.2M loss in
8-K — Impact 4/10
Mar 17, 2026
SEC
Elicio Therapeutics' shelf registration (Form S-3) has become effective, allowing the company to issue unspecified secur
EFFECT — Impact 4/10
Mar 2, 2026
SEC
Elicio Therapeutics filed an S-3/A amendment to update its shelf registration, enabling future public offerings of up to
S-3/A — Impact 6/10
Feb 2, 2026
Insider
Connelly Robert sold 73,600 shares
CEO, President and Director @ $0.00 ($0.00)
Feb 2, 2026
Insider
Connelly Robert sold 147,200 shares
CEO, President and Director @ $0.00 ($0.00)
Feb 2, 2026
Insider
Shah Preetam sold 24,000 shares
See Remarks @ $0.00 ($0.00)
Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
28,111 shares ($223.8K)
Price Targets
$17.50
+23.2% upside
Strong Buy
Current $14.20
Low $17.00
Median $17.50
High $18.00
2 analysts
$17.00
$18.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 28, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 15, 2026 | Ladenburg Thalmann | INITIATE | Buy |
| Mar 13, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 10, 2026 | Rodman & Renshaw | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.49 ▼ -14.0% | $-0.52 — $-0.46 | 26% YoY | 2 |
| Next Q | $-0.41 ▼ -6.4% | $-0.43 — $-0.40 | 31% YoY | 2 |
| Current FY | $-1.95 ▼ -14.4% | $-2.02 — $-1.87 | 25% YoY | 2 |
| Next FY | $-1.76 ▼ -25.7% | $-1.76 — $-1.76 | 10% YoY | 1 |
Latest Reports
NEUTRAL
8-K
4/10
Elicio Therapeutics reported Q1 2026 results with a net loss of $11.8M ($0.65 per share), wider than the $11.2M loss in
May 11, 2026
NEUTRAL
EFFECT
4/10
Elicio Therapeutics' shelf registration (Form S-3) has become effective, allowing the company to issue unspecified secur
Mar 17, 2026
NEUTRAL
Press
5/10
Elicio Therapeutics reported its 2025 financial results and provided updates on its Phase 2 AMPLIFY-7P trial for ELI-002
Mar 12, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $4.0M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $223.8K | TRIM |
| MORGAN STANLEY | $115.8K | DOUBLED |
| BANK OF AMERICA CORP | $9.2K | TRIM |
| WELLS FARGO & COMPANY/MN | $1.6K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 2, 2026 | Connelly Robert | A | $0.00 |
| Feb 2, 2026 | Connelly Robert | A | $0.00 |
| Feb 2, 2026 | Shah Preetam | A | $0.00 |
| Feb 2, 2026 | Shah Preetam | A | $0.00 |
| Feb 2, 2026 | DeMuth Peter | A | $0.00 |
5 institutional holders with $4.3M total value (540,922 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net selling activity: 2 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 496,901 | $4.0M | 91.9% | ADD +41.3% |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 28,111 | $223.8K | 5.2% | TRIM -42.2% |
| 3 | MORGAN STANLEY | 14,553 | $115.8K | 2.7% | DOUBLED +847.5% |
| 4 | BANK OF AMERICA CORP /DE/ | 1,157 | $9.2K | 0.2% | TRIM -67.7% |
| 5 | WELLS FARGO & COMPANY/MN | 200 | $1.6K | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 48,671 | 28,111 | -42.2% | $223.8K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 1,536 | 14,553 | +847.5% | $115.8K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 3,585 | 1,157 | -67.7% | $9.2K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 48,671 | — | $532.5K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 1,250 | 3,585 | +186.8% | $39.2K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 380 | 1,536 | +304.2% | $16.8K | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 321,694 | 454,619 | +41.3% | $3.5M | 2025-Q2 |
| UBS Group AG | TRIM | 21,198 | 6,023 | -71.6% | $46.5K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 842 | 380 | -54.9% | $2.9K | 2025-Q2 |
| VANGUARD GROUP INC | ADD | 245,823 | 321,694 | +30.9% | $2.0M | 2025-Q1 |
| UBS Group AG | DOUBLED | 17 | 21,198 | +124594.1% | $130.6K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 230 | 842 | +266.1% | $5.2K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 848 | 17 | -98.0% | $87.00 | 2024-Q4 |
| CITADEL ADVISORS LLC | EXIT | 12,856 | 0 | -100.0% | $0.00 | 2024-Q4 |
4 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 2, 2026 | Connelly Robert | CEO, President and Director | A | 73,600 | $0.00 | $0.00 |
| Feb 2, 2026 | Connelly Robert | CEO, President and Director | A | 147,200 | $0.00 | $0.00 |
| Feb 2, 2026 | Shah Preetam | See Remarks | A | 24,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Shah Preetam | See Remarks | A | 47,900 | $0.00 | $0.00 |
| Feb 2, 2026 | DeMuth Peter | Chief Scientific Officer | A | 20,800 | $0.00 | $0.00 |
| Feb 2, 2026 | DeMuth Peter | Chief Scientific Officer | A | 41,600 | $0.00 | $0.00 |
| Feb 2, 2026 | Haqq Christopher | See Remarks | A | 25,400 | $0.00 | $0.00 |
| Feb 2, 2026 | Haqq Christopher | See Remarks | A | 50,900 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 4.7/10.
NEUTRAL
8-K
4/10
Elicio Therapeutics reported Q1 2026 results with a net loss of $11.8M ($0.65 per share), wider than
May 11, 2026
NEUTRAL
EFFECT
4/10
Elicio Therapeutics' shelf registration (Form S-3) has become effective, allowing the company to iss
Mar 17, 2026
BEARISH
S-3/A
6/10
Elicio Therapeutics filed an S-3/A amendment to update its shelf registration, enabling future publi
Mar 2, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$17.50 mean target
+23.2% upside
Strong Buy (1.00)
$17.00 Low
$18.00 High
| Metric | Value |
|---|---|
| Current Price | $14.20 |
| Target Low | $17.00 |
| Target Mean | $17.50 |
| Target Median | $17.50 |
| Target High | $18.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.49 | $-0.52 | $-0.46 | 25.8% | -14.0% | 0↑ 1↓ | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.41 | $-0.43 | $-0.40 | 30.8% | -6.4% | 0↑ 1↓ | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-1.95 | $-2.02 | $-1.87 | 24.6% | -14.4% | 0↑ 1↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-1.76 | $-1.76 | $-1.76 | 9.5% | -25.7% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.490 | |
| 7d ago | $-0.520 | +0.030 |
| 30d ago | $-0.430 | -0.060 |
| 60d ago | $-0.430 | -0.060 |
| 90d ago | $-0.370 | -0.120 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 28, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 15, 2026 | Ladenburg Thalmann | INITIATE | — | Buy |
| Mar 13, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 10, 2026 | Rodman & Renshaw | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
short_interest
FTD: ELTX — 61,210 shares ($0.7M) failed to deliver
Settlement: 20260512, Price: $11.61, FTD Value: $710,648.1, ELICIO THERAPEUTICS INC COM
May 11, 2026
earnings_calendar
ELTX Q1 2026 Earnings Scheduled — 2026-05-11
Apr 28, 2026
short_interest
FTD: ELTX — 49,696 shares ($0.6M) failed to deliver
Settlement: 20260428, Price: $11.36, FTD Value: $564,546.56, ELICIO THERAPEUTICS INC COM
Apr 16, 2026
other
Elicio Therapeutics Reports Inducement Grants
<p align="justify">BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage
Mar 12, 2026
earnings
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
<p>BOSTON, March 12, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology co
Feb 10, 2026
short_interest
FTD: ELTX — 129,610 shares ($1.2M) failed to deliver
Settlement: 20260210, Price: $9.51, FTD Value: $1,232,591.1, ELICIO THERAPEUTICS INC COM